All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Meral Beksaç, Ankara University School of Medicine, Ankara, TR, about immunotherapy for MM. We asked, Is there an optimal time to deploy immunotherapies in multiple myeloma?
Is there an optimal time to deploy immunotherapies in multiple myeloma?
In this video, Meral Beksaç talks about how the field of immunotherapy has been advancing rapidly in recent years, with novel monoclonal antibodies (mAbs), alone or with drug conjugates, being developed for use at diagnosis and relapse. Patients today can benefit from the use of anti-CD38 mAbs alongside chemotherapy, whether they are eligible for transplant or not. High rates of measurable residual disease negativity can be achieved by using these treatments.
Figure 1. New ESMO guidelines proposal for the treatment of relapsed multiple myeloma, presented by Meral Beksaç at EBMT 2020, courtesy of María-Victoria Mateos.1Ab, antibody; CAR, chimeric antigen receptor; dara, daratumumab, dex, dexamethasone; IMiD, immunomodulatory imide drug; PI, proteasome inhibitor; pom, pomalidomide.
How should we monitor risk of progression in patients achieving MRD negativity after auto-SCT?
The Multiple Myeloma Hub spoke to Bruno Paiva, University of Navarra, Pamplona, ES, about the importance of monitoring measurable residual disease (MRD)...
Changing practice patterns in autologous transplantation at EBMT centers
During the Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Patrick Hayden presented the results of a retrospective analysis of...
Subscribe to get the best content related to multiple myeloma delivered to your inbox